AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: AstraZeneca, in collaboration with Daiichi Sankyo, is conducting the DESTINY-Lung04 study to evaluate the efficacy and safety of Trastuzumab Deruxtecan as a first-line treatment for patients with unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring HER2 Exon 19 or 20 mutations. This study aims to determine if the drug can improve survival rates and quality of life compared to the current Standard of Care (SoC).
Intervention/Treatment: The study tests Trastuzumab Deruxtecan, an experimental drug administered via intravenous infusion, against the standard treatment regimen of cisplatin or carboplatin combined with pembrolizumab and pemetrexed.
Study Design: This Phase 3, open-label, randomized study involves two parallel treatment arms: one receiving Trastuzumab Deruxtecan and the other receiving the SoC. The primary purpose is treatment-focused, with no masking involved.
Study Timeline: The study began on October 28, 2021, and is currently recruiting participants. The latest update was submitted on July 7, 2025, indicating ongoing progress.
Market Implications: This study could significantly impact AstraZeneca’s stock performance and investor sentiment if Trastuzumab Deruxtecan proves more effective than existing treatments. Success in this trial could position AstraZeneca favorably against competitors in the oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.